Biological characteristics of osteoporosis drugs: the effect of osteoblast–osteoclast coupling
(주)코리아스칼라
- 최초 등록일
- 2023.04.03
- 최종 저작일
- 2019.03
- 7페이지/ 어도비 PDF
- 가격 4,000원
* 본 문서는 배포용으로 복사 및 편집이 불가합니다.
서지정보
ㆍ발행기관 : 대한구강생물학회
ㆍ수록지정보 : International Journal of Oral Biology / 44권 / 1호
ㆍ저자명 : Sung-Jin Kim, Seok Jun Moon, Jeong Taeg Seo
목차
Introduction
Anti-resorptive Drugs
1. Bisphosphonates
2. Receptor activator of nuclear factor kappa-B ligand antibody (Denosumab)
3. Hormone replacement therapy: estrogen therapy
4. Selective estrogen receptor modulators Anabolic Drugs
1. Parathyroid hormone receptor agonists
Conclusions
References
영어 초록
Osteoporosis is a common disease characterized by bone mass reduction, leading to an increased risk of bone fracture, and it is caused by an imbalance of osteoblastic bone formation and osteoclastic bone resorption. Current osteoporosis drugs aim to reduce the risk of bone fracture, either by increasing osteoblastic bone formation or decreasing osteoclastic bone resorption. However, osteoblasts and osteoclasts are closely coupled, such that any reagent altering the differentiation or activity of one eventually affects the other. This tight coupling between osteoblasts and osteoclasts not only limits the therapeutic efficacy but also threatens the safety of osteoporosis drugs. This review will discuss the biological mechanisms of action of currently approved medications for osteoporosis treatment, focusing on the osteoblast–osteoclast coupling.
참고 자료
없음
"International Journal of Oral Biology"의 다른 논문